Mackenzie G. The definition and classification of pneumonia. Pneumonia. 2016;8(1):1–5.
Medical News Today. What to know about bacterial pneumonia. 2019. Available from: https://www.medicalnewstoday.com/articles/312565.
Pahal P, Rajasurya V, Sharma S. Typical Bacterial Pneumonia. Treasure Island: StatPearls Publishing; 2020.
Temesgen D, Bereded F, Derbie A, Biadglegne F. Bacteriology of community acquired pneumonia in adult patients at Felege Hiwot referral hospital, Northwest Ethiopia: a cross-sectional study. Antimicrob Resist Infect Control. 2019;8(1):1–8.
Shebl E, Gulick PG. Nosocomial Pneumonia. Treasure Island: StatPearls; 2020.
Eshwara V, Mukhopadhyay C, Rello J. Community-acquired bacterial pneumonia in adults: an update. Indian J Med Res. 2020;151(4):287–302.
Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1736–88.
Cilloniz C, Martin-Loeches I, Garcia-Vidal C, San Jose A, Torres A. Microbial etiology of pneumonia: epidemiology, diagnosis and resistance patterns. Int J Mol Sci. 2016;17(12):2120.
Miyashita N, Yamauchi Y. Bacterial pneumonia in elderly Japanese populations. Jpn Clin Med. 2018;9:1179670717751433.
Ticona JH, Zaccone VM, McFarlane IM. Community-acquired pneumonia: a focused review. Am J Med Case Rep. 2021;9(1):45–52.
DerSarkissian C. What is bacterial pneumonia? 2020. Available from: https://www.webmd.com/lung/bacterial-pneumonia.
Wong JL, Evans SE. Bacterial pneumonia in patients with cancer: novel risk factors and management. Clin Chest Med. 2017;38(2):263–77.
Henig O, Kaye KS. Bacterial pneumonia in older adults. Infect Dis Clin. 2017;31(4):689–713.
Hanada S, Pirzadeh M, Carver KY, Deng JC. Respiratory viral infection-induced microbiome alterations and secondary bacterial pneumonia. Front Immunol. 2018;9:2640.
Marangu D, Zar HJ. Childhood pneumonia in low-and-middle-income countries: an update. Paediatr Respir Rev. 2019;32:3–9.
Jean S-S, Chang Y-C, Lin W-C, Lee W-S, Hsueh P-R, Hsu C-W. Epidemiology, treatment, and prevention of nosocomial bacterial pneumonia. J Clin Med. 2020;9(1):275.
del Valle-Mendoza J, Silva-Caso W, Cornejo-Tapia A, Orellana-Peralta F, Verne E, Ugarte C, et al. Molecular etiological profile of atypical bacterial pathogens, viruses and coinfections among infants and children with community acquired pneumonia admitted to a national hospital in Lima, Peru. BMC Res Notes. 2017;10(1):1–6.
Chen G, Xu K, Sun F, Sun Y, Kong Z, Fang B. Risk factors of multidrug-resistant Bacteria in lower respiratory tract infections: a systematic review and Meta-analysis. Can J Infect Dis Med Microbiol. 2020;2020:7268519.
Gao B, Li X, Yang F, Chen W, Zhao Y, Bai G, et al. Molecular epidemiology and risk factors of ventilator-associated pneumonia infection caused by carbapenem-resistant enterobacteriaceae. Front Pharmacol. 2019;10:262.
Cillóniz C, Dominedò C, Torres A. Multidrug resistant gram-negative bacteria in community-acquired pneumonia. Ann Update Intensive Care Emerg Med. 2019;2019:459–75.
Sader HS, Castanheira M, Mendes RE, Flamm RK. Frequency and antimicrobial susceptibility of gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015–17). J Antimicrob Chemother. 2018;73(11):3053–9.
Rouby J-J, Sole-Lleonart C, Rello J. Ventilator-associated pneumonia caused by multidrug-resistant gram-negative bacteria: understanding nebulization of aminoglycosides and colistin. Intensive Care Med. 2020;46(4):766–70.
Kidd JM, Kuti JL, Nicolau DP. Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria. Expert Opin Pharmacother. 2018;19(4):397–408.
Cillóniz C, Dominedò C, Torres A. Multidrug resistant gram-negative bacteria in community-acquired pneumonia. Crit Care. 2019;23(1):1–9.
Roquilly A, Torres A, Villadangos J, Netea M, Dickson R, Becher B, et al. Pathophysiological role of respiratory dysbiosis in hospital-acquired pneumonia. Lancet Respir Med. 2019;7(8):710–20.
Luan Y, Sun Y, Duan S, Zhao P, Bao Z. Pathogenic bacterial profile and drug resistance analysis of community-acquired pneumonia in older outpatients with fever. J Int Med Res. 2018;46(11):4596–604.
Bjarnason A, Westin J, Lindh M, Andersson L-M, Kristinsson KG, Löve A, et al. Incidence, etiology, and outcomes of community-acquired pneumonia: a population-based study. Open forum infectious diseases. US: Oxford University Press; 2018.
Sattar SBA, Sharma S. Bacterial Pneumonia. Treasure Island: StatPearls Publishing; 2020.
Malézieux-Picard A, Parent T, Roux X, Fassier T, Müller F, Prendki V. Pneumonia prevention in the elderly patients: the other sides. Aging Clin Exp Res. 2021;33(4):1091–100.
Muthumbi E, Lowe BS, Muyodi C, Getambu E, Gleeson F, Scott JAG. Risk factors for community-acquired pneumonia among adults in Kenya: a case–control study. Pneumonia. 2017;9(1):1–9.
Jokinen J, Scott JAG. Estimating the proportion of pneumonia attributable to pneumococcus in Kenyan adults: latent class analysis. Epidemiology. 2010;21(5):719.
Onyedum CC, Chukwuka J. Admission profile and management of community acquired pneumonia in Nigeria-5 year experience in a tertiary hospital. Respir Med. 2011;105(2):298–302.
Markos Y, Dadi AF, Demisse AG, Ayanaw Habitu Y, Derseh BT, Debalkie G. Determinants of under-five pneumonia at Gondar University hospital, Northwest Ethiopia: an unmatched case-control study. J Environ Public Health. 2019;2019:1–8.
Gordon S, Graham S. Epidemiology of respiratory disease in Malawi. Malawi Med J. 2006;18(3):134–46.
Aston SJ, Ho A, Jary H, Huwa J, Mitchell T, Ibitoye S, et al. Etiology and risk factors for mortality in an adult community-acquired pneumonia cohort in Malawi. Am J Respir Crit Care Med. 2019;200(3):359–69.
Ojuawo OB, Desalu OO, Fawibe AE, Ojuawo AB, Aladesanmi AO, Opeyemi CM, et al. Clinical and microbiological profile of adult inpatients with community acquired pneumonia in Ilorin, north central, Nigeria. Afr Health Sci. 2020;20(4):1655–68.
Dessie T, Jemal M, Maru M, Tiruneh M. Multiresistant bacterial pathogens causing bacterial pneumonia and analyses of potential risk factors from Northeast Ethiopia. Int J Microbiol. 2021;2021:6680343.
Assefa M, Tigabu A, Belachew T, Tessema B. Bacterial profile, antimicrobial susceptibility patterns, and associated factors of community-acquired pneumonia among adult patients in Gondar, Northwest Ethiopia: a cross-sectional study. PLoS One. 2022;17(2):e0262956.
Kishimbo P, Sogone NM, Kalokola F, Mshana SE. Prevalence of gram negative bacteria causing community acquired pneumonia among adults in Mwanza City, Tanzania. Pneumonia. 2020;12(1):1–9.
Ibrahim A. Bacterial etiology of community acquired pneumonia and their antimicrobial susceptibility in patients admitted to alshaab teaching hospital. Sudan Med Lab J. 2018;6(1):78–94.
Torres A, Cillóniz C. Clinical management of bacterial pneumonia: Springer; 2015.
Pássaro L, Harbarth S, Landelle C. Prevention of hospital-acquired pneumonia in non-ventilated adult patients: a narrative review. Antimicrob Resist Infect Control. 2016;5(1):1–11.
Tassew SG, Alebachew Woldu M, Amogne Degu W, Shibeshi W. Management of hospital-acquired infections among patients hospitalized at Zewditu memorial hospital, Addis Ababa, Ethiopia: a prospective cross-sectional study. PLoS One. 2020;15(4):e0231949.
Nusrat T, Akter N, Rahman NAA, Godman BD, Rozario DT, Haque M. Antibiotic resistance and sensitivity pattern of Metallo-β-Lactamase Producing Gram-Negative Bacilli in ventilator-associated pneumonia in the intensive care unit of a public medical school hospital in Bangladesh. Hosp Pract. 2020;48(3):128–36.
Sattar F, Quadros D, Olang P, Chokwe T. Incidence of ventilator-associated pneumonia in the critical care unit at Kenyatta National Hospital, a public tertiary care hospital. East Afr Med J. 2018;95(6):1613–23.
Saied W, Mourvillier B, Cohen Y, Ruckly S, Reignier J, Marcotte G, et al. A comparison of the mortality risk associated with ventilator-acquired bacterial pneumonia and nonventilator ICU-acquired bacterial pneumonia. Crit Care Med. 2019;47(3):345–52.
Cilloniza C, Dominedo C, Torresa A. CURRENT OPINION an overview of guidelines for the management of hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant gram-negative bacteria. Curr Opin Infect Dis. 2019;32:656–62.
Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY antimicrobial surveillance program, 2009–2012. Int J Antimicrob Agents. 2014;43(4):328–34.
El-Nawawy A, Ramadan MA-F, Antonios MA-M, Arafa SA-F, Hamza E. Bacteriologic profile and susceptibility pattern of mechanically ventilated paediatric patients with pneumonia. J Glob Antimicrob Resist. 2019;18:88–94.
Mazloomirad F, Hasanzadeh S, Sharifi A, Nikbakht G, Roustaei N, Khoramrooz SS. Identification and detection of pathogenic bacteria from patients with hospital-acquired pneumonia in southwestern Iran; evaluation of biofilm production and molecular typing of bacterial isolates. BMC Pulm Med. 2021;21(1):1–11.
Feng D-Y, Zhou Y-Q, Zou X-L, Zhou M, Wu W-B, Chen X-X, et al. Factors influencing mortality in hospital-acquired pneumonia caused by gram-negative bacteria in China. J Infect Public Health. 2019;12(5):630–3.
Bassetti M, Righi E, Vena A, Graziano E, Russo A, Peghin M. Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug-resistant/extensively drug-resistant/pandrug-resistant bacteria. Curr Opin Crit Care. 2018;24(5):385–93.
Gupta R, Malik A, Rizvi M, Ahmed M, Singh A. Epidemiology of multidrug-resistant gram-negative pathogens isolated from ventilator-associated pneumonia in ICU patients. J Glob Antimicrob Resist. 2017;9:47–50.
Yehia FAA, Serry FK, Abdullatif H, M El-Ganiny A. Prevalence and antimicrobial susceptibility of bacterial pathogens isolated from ventilator associated pneumonia (VAP) patients. Zagazig. J Pharm Sci. 2017;26(1):39–47.
Ahsan AA, Barai L, Faruq MO, Fatema K, Ahmed F, Saha DK, et al. Antibiotic resistance pattern among bacteria causing ventilator associated pneumonia in an intensive care unit of Bangladesh. Bangladesh Crit Care J. 2016;4(2):69–73.
Nguyen TT, Nguyen KT. Hospital-acquired pneumonia in an intensive care unit in Vietnam: clinical characteristics and pathogenic bacteria. Pharmaceut Sci Asia. 2020;47(4):387–98.
Nyawale HA. Incidence, bacteria etiology and factors associated with ventilator associated pneumonia among patients on mechanical ventilator in intensive care units at tertiary hospitals. Dar Es Salaam: Muhimbili University of Health and Allied Sciences; 2020.
Gu W-J, Wang F, Tang L, Bakker J, Liu J-C. Colistin for the treatment of ventilator-associated pneumonia caused by multidrug-resistant gram-negative bacteria: a systematic review and meta-analysis. Int J Antimicrob Agents. 2014;44(6):477–85.
Ruppé É, Woerther P-L, Barbier F. Mechanisms of antimicrobial resistance in gram-negative bacilli. Ann Intensive Care. 2015;5(1):1–15.
Breijyeh Z, Jubeh B, Karaman R. Resistance of gram-negative bacteria to current antibacterial agents and approaches to resolve it. Molecules. 2020;25(6):1340.
Asfaw T. Review on hospital wastewater as a source of emerging drug resistance pathogens. J Res Environ Sci Toxicol. 2018;7(2):47–52.
Cerceo E, Deitelzweig SB, Sherman BM, Amin AN. Multidrug-resistant gram-negative bacterial infections in the hospital setting: overview, implications for clinical practice, and emerging treatment options. Microb Drug Resist. 2016;22(5):412–31.
Maruyama T, Fujisawa T, Ishida T, Ito A, Oyamada Y, Fujimoto K, et al. A therapeutic strategy for all pneumonia patients: a 3-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy. Clin Infect Dis. 2019;68(7):1080–8.
Watkins RR, Van Duin D. Current trends in the treatment of pneumonia due to multidrug-resistant gram-negative bacteria. F1000Research. 2019;8.
Rubio-Perez I, Martin-Perez E, Domingo-García D, Garcia-Olmo D. Specific clinical profile and risk factors for mortality in general surgery patients with infections by multi-drug–resistant gram-negative bacteria. Surg Infect (Larchmt). 2017;18(5):625–33.
Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A, et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2013;188(8):985–95.
Prina E, Ranzani OT, Polverino E, Cillóniz C, Ferrer M, Fernandez L, et al. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc. 2015;12(2):153–60.
Aliberti S, Cilloniz C, Chalmers JD, Zanaboni AM, Cosentini R, Tarsia P, et al. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective. Thorax. 2013;68(11):997–9.
Eugenin EA. Community-acquired pneumonia infections by Acinetobacter baumannii: how does alcohol impact the antimicrobial functions of macrophages? Virulence. 2013;4(6):435–6.
Inghammar M, Borand L, Goyet S, Rammaert B, Te V, Lorn Try P, et al. Community-acquired pneumonia and gram-negative bacilli in Cambodia—incidence, risk factors and clinical characteristics. Trans R Soc Trop Med Hyg. 2018;112(2):57–63.
Yun Z, Hong Z, Dengchuan Z, Afang Z, Jiabin L. Risk factor analysis of pan-drug resistant Acinetobacter baumannii-induced ventilator-associated pneumonia in ICU. Indian J Pharm Sci. 2020:8–11.
Teramoto SYK, Hizawa N. Update on the pathogenesis and management of pneumonia in the elderly-roles of aspiration pneumonia. Respir Investig. 2015;53(5):178–84.
Wang Y-h. Current progress of research on intestinal bacterial translocation. Microb Pathog. 2021;152:104652.
Seki M. Emerging the notion and definition of NHCAP: what is the NHCAP? Why aspiration pneumonia is important in NHCAP? Aspiration pneumonia: Springer; 2020. p. 219–27.
Sasegbon A, Hamdy S. The anatomy and physiology of normal and abnormal swallowing in oropharyngeal dysphagia. Neurogastroenterol Motil. 2017;29(11):e13100.
Nagpal R, Yadav H. Bacterial translocation from the gut to the distant organs: an overview. Ann Nutr Metab. 2017;71(Suppl. 1):11–6.
da Cruz DG, de Magalhães RF, Padilha GA, da Silva MC, Braga CL, Silva AR, et al. Impact of positive biphasic pressure during low and high inspiratory efforts in Pseudomonas aeruginosa-induced pneumonia. PLoS One. 2021;16(2):e0246891.
de Carvalho Baptista IM, Martinho FC, Nascimento GG, da Rocha Santos CE, do Prado RF, Valera MC. Colonization of oropharynx and lower respiratory tract in critical patients: risk of ventilator-associated pneumonia. Arch Oral Biol. 2018;85:64–9.
Cepas V, Soto SM. Relationship between virulence and resistance among gram-negative bacteria. Antibiotics. 2020;9(10):719.
Viswanathan P, Suneeva S, Rathinam P. Quorum sensing in pathogenesis and virulence. Quorum sensing vs quorum quenching: a battle with no end in sight: Springer; 2015. p. 39–50.
Méndez R, Menéndez R, Cillóniz C, Amara-Elori I, Amaro R, González P, et al. Initial inflammatory profile in community-acquired pneumonia depends on time since onset of symptoms. Am J Respir Crit Care Med. 2018;198(3):370–8.
Redinger J, Albert T. Approach to dyspnea. chalk talks in internal medicine: Springer; 2020. p. 197–202.
Franquet T. Imaging of community-acquired pneumonia. J Thorac Imaging. 2018;33(5):282–94.
Noviello S, Huang DB. The basics and the advancements in diagnosis of bacterial lower respiratory tract infections. Diagnostics. 2019;9(2):37.
Claassen CC, Keenan WJ. Challenging the “culture” of the tracheal aspirate. NeoReviews. 2019;20(3):e145–e51.
Gadsby NJ, Russell CD, McHugh MP, Mark H, Conway Morris A, Laurenson IF, et al. Comprehensive molecular testing for respiratory pathogens in community-acquired pneumonia. Clin Infect Dis. 2016;62(7):817–23.
Kitsios GD, Fitch A, Manatakis DV, Rapport SF, Li K, Qin S, et al. Respiratory microbiome profiling for etiologic diagnosis of pneumonia in mechanically ventilated patients. Front Microbiol. 2018;9:1413.
Akter S, Shamsuzzaman S, Jahan F. Community acquired bacterial pneumonia: aetiology, laboratory detection and antibiotic susceptibility pattern. Malays J Pathol. 2014;36(2):97–103.
Peiffer-Smadja N, Bouadma L, Mathy V, Allouche K, Patrier J, Reboul M, et al. Performance and impact of a multiplex PCR in ICU patients with ventilator-associated pneumonia or ventilated hospital-acquired pneumonia. Crit Care. 2020;24(1):1–10.
Murphy CN, Fowler R, Balada-Llasat JM, Carroll A, Stone H, Akerele O, et al. Multicenter evaluation of the BioFire FilmArray pneumonia/pneumonia plus panel for detection and quantification of agents of lower respiratory tract infection. J Clin Microbiol. 2020;58(7):e00128–0.
Edin A, Eilers H, Allard A. Evaluation of the Biofire Filmarray pneumonia panel plus for lower respiratory tract infections. Infect Dis. 2020;52(7):479–88.
Acharya KP, Wilson RT. Antimicrobial resistance in Nepal. Front Med. 2019;6:105.
Qi L, Li H, Zhang C, Liang B, Li J, Wang L, et al. Relationship between antibiotic resistance, biofilm formation, and biofilm-specific resistance in Acinetobacter baumannii. Front Microbiol. 2016;7:483.
Arzanlou M, Chai WC, Venter H. Intrinsic, adaptive and acquired antimicrobial resistance in gram-negative bacteria. Essays Biochem. 2017;61(1):49–59.
Eichenberger EM, Thaden JT. Epidemiology and mechanisms of resistance of extensively drug resistant gram-negative bacteria. Antibiotics. 2019;8(2):37.
Öztürk H, Ozkirimli E, Özgür A. Classification of beta-lactamases and penicillin binding proteins using ligand-centric network models. PLoS One. 2015;10(2):e0117874.
Bandić-Pavlović D, Zah-Bogović T, Žižek M, Bielen L, Bratić V, Hrabač P, et al. Gram-negative bacteria as causative agents of ventilator-associated pneumonia and their respective resistance mechanisms. J Chemother. 2020;32(7):344–58.
Bonomo RA. β-Lactamases: a focus on current challenges. Cold Spring Harb Perspect Med. 2017;7(1):a025239.
Dumaru R, Baral R, Shrestha LB. Study of biofilm formation and antibiotic resistance pattern of gram-negative Bacilli among the clinical isolates at BPKIHS. Dharan BMC Res Notes. 2019;12(1):1–6.
Baidya S, Sharma S, Mishra SK, Kattel HP, Parajuli K, Sherchand JB. Biofilm formation by pathogens causing ventilator-associated pneumonia at intensive care units in a tertiary care hospital: an armor for refuge. Biomed Res Int. 2021;2021:1–10.
Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380(6):517–27.
File TM Jr, Goldberg L, Das A, Sweeney C, Saviski J, Gelone SP, et al. Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the phase III lefamulin evaluation against pneumonia (LEAP 1) trial. Clin Infect Dis. 2019;69(11):1856–67.
McCurdy S, Keedy K, Lawrence L, Nenninger A, Sheets A, Quintas M, et al. Efficacy of delafloxacin versus moxifloxacin against bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): microbiology results from the delafloxacin phase 3 CABP trial. Antimicrob Agents Chemother. 2020;64(3):e01949–19.
Vardakas KZ, Trigkidis K, Falagas M. Fluoroquinolones or macrolides in combination with β-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis. Clin Microbiol Infect. 2017;23(4):234–41.
Wunderink RG, Matsunaga Y, Ariyasu M, Clevenbergh P, Echols R, Kaye KS, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2021;21(2):213–25.
Torres A, Rank D, Melnick D, Rekeda L, Chen X, Riccobene T, et al. Randomized trial of ceftazidime-avibactam vs meropenem for treatment of hospital-acquired and ventilator-associated bacterial pneumonia (REPROVE): analyses per US FDA–specified end points. Open forum infectious diseases. US: Oxford University Press; 2019.
Titov I, Wunderink RG, Roquilly A, Rodríguez Gonzalez D, David-Wang A, Boucher HW, et al. A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem/cilastatin/relebactam versus piperacillin/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 Study). Clin Infect Dis. 2021;73(11):e4539–48.
Liscio JL, Mahoney MV, Hirsch EB. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant gram-negative bacterial infections. Int J Antimicrob Agents. 2015;46(3):266–71.
Chang Liu Y-TZ, Peng Z-Y, Zhou Q, Hu B, Zhou H, Li J-G. Aerosolized amikacin as adjunctive therapy of ventilator-associated pneumonia caused by multidrug-resistant gram-negative bacteria: a single-center randomized controlled trial. Chin Med J (Engl). 2017;130(10):1196–201.
Aygun F, Aygun FD, Varol F, Durak C, Cokugraş H, Camcioglu Y, et al. Can nebulised Colistin therapy improve outcomes in critically ill children with multi-drug resistant gram-negative bacterial pneumonia? Antibiotics. 2019;8(2):40.
Feng JY, Peng CK, Sheu CC, Lin YC, Chan MC, Wang SH, et al. Efficacy of adjunctive nebulized colistin in critically ill patients with nosocomial carbapenem-resistant Gram-negative bacterial pneumonia: a multi-centre observational study. Clin Microbiol Infect. 2021;27(10):1465–73.
Abdellatif S, Trifi A, Daly F, Mahjoub K, Nasri R, Lakhal SB. Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial. Ann Intensive Care. 2016;6(1):1–11.
Manohar P, Nachimuthu R, Lopes BS. The therapeutic potential of bacteriophages targeting gram-negative bacteria using galleria mellonella infection model. BMC Microbiol. 2018;18(1):1–11.
Lood R, Winer BY, Pelzek AJ, Diez-Martinez R, Thandar M, Euler CW, et al. Novel phage lysin capable of killing the multidrug-resistant gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model. Antimicrob Agents Chemother. 2015;59(4):1983–91.
Anand T, Virmani N, Kumar S, Mohanty AK, Pavulraj S, Bera BC, et al. Phage therapy for treatment of virulent Klebsiella pneumoniae infection in a mouse model. J Glob Antimicrob Resist. 2020;21:34–41.
Raz A, Serrano A, Hernandez A, Euler CW, Fischetti VA. Isolation of phage lysins that effectively kill Pseudomonas aeruginosa in mouse models of lung and skin infection. Antimicrob Agents Chemother. 2019;63(7):e00024–19.
Huang L, Huang S, Jiang L, Tan J, Yan X, Gou C, et al. Characterization and sequencing of a novel phage Abp95 against multi-genotypes of Carbapenem-resistant Acinetobacter baumannii. 2021.
Zhang Y, Meng B, Wei X, Li Y, Wang X, Zheng Y, et al. Evaluation of phage therapy for pulmonary infection of mouse by liquid aerosol-exposure Pseudomonas aeruginosa. Infect Drug Resist. 2021;14:4457.
Bann SJ, Ballantine RD, Cochrane SA. The tridecaptins: non-ribosomal peptides that selectively target gram-negative bacteria. RSC Med Chem. 2021;12(4):538–51.
Pantel L, Florin T, Dobosz-Bartoszek M, Racine E, Sarciaux M, Serri M, et al. Odilorhabdins, antibacterial agents that cause miscoding by binding at a new ribosomal site. Mol Cell. 2018;70(1):83–94. e7.
Zhang J, Liang X, Zhang S, Song Z, Wang C, Xu Y, et al. A novel natural compound with promising anti-biofilm activity against gram-negative pathogenic bacteria. Front Microbiol. 2021;11:3480.
Islam S, Chisti MJ, Ahmed M, Anwar N, Lehmann C. Bacterial resistance in pneumonia in developing countries—a role for Iron chelation. Trop Med Infect Dis. 2019;4(2):59.
Opoku-Temeng CKS, DeLeo FR. Klebsiella pneumoniae capsule polysaccharide as a target for therapeutics and vaccines. Comput Struct Biotechnol J. 2019;1(17):1360–6.
Rodrigues MX, Yang Y, de Souza Meira EB Jr, do Carmo Silva J, Bicalho RC. Development and evaluation of a new recombinant protein vaccine (YidR) against Klebsiella pneumoniae infection. Vaccine. 2020;38(29):4640–8.
Feldman MF, Bridwell AEM, Scott NE, Vinogradov E, McKee SR, Chavez SM, et al. A promising bioconjugate vaccine against hypervirulent Klebsiella pneumoniae. Proc Natl Acad Sci. 2019;116(37):18655–63.
Kumar A, Harjai K, Chhibber S. Early cytokine response to lethal challenge of Klebsiella pneumoniae averted the prognosis of pneumonia in FyuA immunized mice. Microb Pathog. 2020;144:104161.
Adlbrecht C, Wurm R, Depuydt P, Spapen H, Lorente JA, Staudinger T, et al. Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients—a randomized clinical trial. Crit Care. 2020;24(1):1–10.
Cabral MP, Correia A, Vilanova M, Gärtner F, Moscoso M, García P, et al. A live auxotrophic vaccine confers mucosal immunity and protection against lethal pneumonia caused by Pseudomonas aeruginosa. PLoS Pathog. 2020;16(2):e1008311.
Gajdács M, Urbán E. Prevalence and antibiotic resistance of Stenotrophomonas maltophilia in respiratory tract samples: a 10-year epidemiological snapshot. Health Serv Res Manag Epidemiol. 2019;6:2333392819870774.
Shah MD, Coe KE, El Boghdadly Z, Wardlow LC, Dela-Pena JC, Stevenson KB, et al. Efficacy of combination therapy versus monotherapy in the treatment of Stenotrophomonas maltophilia pneumonia. J Antimicrob Chemother. 2019;74(7):2055–9.
Guerci P, Bellut H, Mokhtari M, Gaudefroy J, Mongardon N, Charpentier C, et al. Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study. Crit Care. 2019;23(1):1–13.
Saied WI, Merceron S, Schwebel C, Le Monnier A, Oziel J, Garrouste-Orgeas M, et al. Ventilator-associated pneumonia due to Stenotrophomonas maltophilia: risk factors and outcome. J Infect. 2020;80(3):279–85.
Canivet C, Teysseyre L, Aujoulat T, Caron M, Nativel M, Miltgen G, et al. Risk factors for a first episode of ventilator-associated pneumonia caused by Stenotrophomonas maltophilia. 2022.
Imoto W, Kaneko Y, Yamada K, Kuwabara G, Yamairi K, Shibata W, et al. A mouse model of rapidly progressive fatal haemorrhagic pneumonia caused by Stenotrophomonas maltophilia. J Glob Antimicrob Resist. 2020;23:450–5.
Velázquez-Acosta C, Zarco-Márquez S, Jiménez-Andrade MC, Volkow-Fernández P, Cornejo-Juárez P. Stenotrophomonas maltophilia bacteremia and pneumonia at a tertiary-care oncology center: a review of 16 years. Support Care Cancer. 2018;26(6):1953–60.
Kim S-H, Cha MK, Kang C-I, Ko J-H, Huh K, Cho SY, et al. Pathogenic significance of hemorrhagic pneumonia in hematologic malignancy patients with Stenotrophomonas maltophilia bacteremia: clinical and microbiological analysis. Eur J Clin Microbiol Infect Dis. 2019;38(2):285–95.
Zha L, Zhang D, Pan L, Ren Z, Li X, Zou Y, et al. Tigecycline in the treatment of ventilator-associated pneumonia due to Stenotrophomonas maltophilia: a multicenter retrospective cohort study. Infect Dis Ther. 2021;10(4):2415–29.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.